Pharmacy World and Science

, Volume 24, Issue 2, pp 61–66 | Cite as

An evaluation of quinolone prescribing in a group of acute hospitals: development of an objective measure of usage

  • C. CurtisEmail author
  • R. Fitzpatrick
  • J.F. Marriott


Objectives: To develop an objective measure to enable hospital Trusts to compare their use of antibiotics.Design:Self-completion, postal questionnaire with telephone follow up.Sample: 4 hospital trusts in the English Midlands.Results: The survey showed that it was possible to collect data concerning the number of Defined Daily Doses (DDD's) of quinolone antibiotic dispensed per Finished Consultant Episode (FCE) in each Trust. In the 4 trusts studied the mean DDD/FCE was 0.197 (range 0.117 to 0.258). This indicates that based on a typical course length of 5 days, 3.9% of patient episodes resulted in the prescription of a quinolone antibiotic. Antibiotic prescribing control measures in each Trust were found to be comparable. Conclusion: The measure will enable Trusts to objectively compare their usage of quinolone antibiotics and use this information to carry out clinical audit should differences be recorded. This is likely to be applicable to other groups of antibiotics.

Antibiotic Ciprofloxacin Quinolone Resistance 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Statistics of prescriptions dispensed in community: England, 1988-97, Statistical Bulletin, 1998/Q4. Department of Health, London 1998.Google Scholar
  2. 2.
    Medicines and the NHS: A Guide for Directors. London: Drug and Therapeutics Bulletin, Consumer's Association 1997.Google Scholar
  3. 3.
    The Performance Management of Medicines Management in NHS Hospitals. Department of Health. London. 2001.Google Scholar
  4. 4.
    Hospital Prescribing Information Project, Second report. Analysis for Health Authority Prescribing Advisers and Senior Hospital Professionals/Managers, National Prescribing Centre, May 1999.Google Scholar
  5. 5.
    Giamarellou H, Antoniadou A. The Effect of monitoring of antibiotic use on decreasing antibiotic resistance in the hospital. Ciba Foundation Symposium. 1997;207:76-86, discussion 86-92.Google Scholar
  6. 6.
    Gaunt P N, Piddock J V. Ciprofloxacin resistant Campylobacter spp. in humans: an epidemiological and laboratory study. J Antimicrob Chem. 1996;37:747-57.Google Scholar
  7. 7.
    Select Committee on Science and Technology. Sub-committee 1 (House of Lords). 7th report [session 1997-8]: Resistance to antibiotics and other antimicrobial agents. [HL] 81-1. London: The Stationery Office, 1998.Google Scholar
  8. 8.
    Standing Medical Advisory Committee (Department of Health). The path of least resistance. Main report. London: Department of Health, 1998.Google Scholar
  9. 9.
    Resistance to antibiotics and other antimicrobial agents. NHS Executive. Health Service Circular. HSC 1999/049. 10 Department of Health. The management and control of hospital infection (HSC 2000/002). February 2000.Google Scholar
  10. 10.
    Department of Health. The management and control of hospitalinfection (HSC 2000/002). February 2000.Google Scholar
  11. 11.
    Bogle S.M, Harris C.M. Measuring prescribing: the shortcomings of the item. BMJ. 1994;308:637-40.Google Scholar
  12. 12.
    Whiteside H., Scrivener G., Roberts D., Walley T. ADQs: a new measure of prescribing volume. Prescriber. May 2001;12:23-9.Google Scholar
  13. 13.
    Natsch S., Hekster Y.A., de Jong R., Heerdink E.R., Herings R.M.C., van der Meer. Application of the ATC/DDD methodology to monitor antibiotic drug use. Eur. J. Clin. Microbiol. Infect. Dis. 1998;17:20-4.Google Scholar
  14. 14.
    World Health Organisation: Guidelines for ATC classification and DDD assignment. Norsk Medisinaldepot, Oslo 1996.Google Scholar
  15. 15.
    Cosentino M, Leoni O., Banfi F., Lecchini S., Frigo G. An approach for the estimation of drug prescribing using the defined daily dose methodology and drug dispensation data. Eur. J. Clin. Pharmacol, 2000;56: 513-7.Google Scholar
  16. 16.
    Monnet D., Lennox K., Archibald L., Phillips L. et al. Antimicrobial use and resistance in eight US hospitals: Complexities of analysis and modeling. Infect. Control Hosp. Epidemiol 1998;19:388-94.Google Scholar
  17. 17.
    Marvin V., Dowdall T. Switching ciprofloxacin from IV to oral. Pharmacy in Practice 1998;5:218-21.Google Scholar
  18. 18.
    Jensen K.M., Paladino J.A. Cost Effectiveness of abbreviating the duration of intravenous antibacterial therapy with oral fluoroquinolones. Pharmacoeconomics. 1997;11:64-7.Google Scholar
  19. 19.
    Amodio-Groton M., Madu A., Madu C.N., Briceland L.L., Seligman M., McMaster P. et al. Sequential parenteral and oral ciprofloxacin regimen versus parenteral therapy for bacteraemia: a pharmacoeconomic analysis. Ann. Pharmacother. 1996;30:596-602.Google Scholar
  20. 20.
    Department of Health. UK Antimicrobial resistance strategy and action plan. 2000. London.Google Scholar
  21. 21.
    British Pharmaceutical Conference Report, Birmingham 2000. Pharm J. 2000;265:397-400.Google Scholar
  22. 22.
    Working Party of the British Society for Antimicrobial Chemotherapy. Hospital antibiotic Control measures in the UK. J. Antimicrob. Chemother. 1994;34:21-42.Google Scholar

Copyright information

© Kluwer Academic Publishers 2002

Authors and Affiliations

  1. 1.Queen's HospitalBurton upon Trent, StraffordshireUK
  2. 2.Pharmacy DepartmentNorth Staffordshire HospitalStoke on TrentUK
  3. 3.Aston Pharmacy SchoolAston UniversityBirminghamUK

Personalised recommendations